Jette 2005 — CJC-1295 Preclinical Discovery

Endocrinology·July 1, 2005

Lucie Jetté, Roger Léger, Karen Thibaudeau, Corinne Benquet, Martin Robitaille, Isabelle Pellerin, Véronique Paradis, Pieter van Wyk, Khan Pham, Dominique P Bridon

Summary

CJC-1295 showed 4-fold increase in GH area under curve compared to hGRF(1-29). Present in plasma beyond 72 hours. Identified as stable and active hGRF(1-29) analog with extended plasma half-life.

Study Details

Study Design

Preclinical in vitro and in vivo study

Indication

DAC-GHRH analog development

Intervention

Various preclinical

Species

Rat

Risk of Bias Assessment

ConjuChem internal research